金陵药业：分公司收到水解蛋白注射液药品再注册批准通知书

Core Viewpoint - Jinling Pharmaceutical announced that its subsidiary, Fuzhou Meifeng Pharmaceutical Factory, received a drug re-registration approval notice from the Fujian Provincial Drug Administration for hydrolyzed protein injection, which is used for severe amino acid deficiency due to serious surgical trauma and large-area burns, as well as low protein levels caused by various diseases [2] Summary by Relevant Sections - Product Approval - The drug hydrolyzed protein injection is aimed at treating severe amino acid deficiency and low protein levels [2] - The approval notice will facilitate the resumption of normal production and sales of the drug [2] - Production Resumption Requirements - Due to a long period of non-production, the company must apply for on-site inspections from provincial drug supervision authorities and ensure that three batches of products pass inspection before the drug can be marketed [2] - Impact on Financial Performance - The approval is expected to benefit the drug's production and sales but will not have a significant impact on the company's recent operating performance [2]